Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026

50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

Unprecedented Efficacy in Both Refractory Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS)

PHILADELPHIA and MADRID, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, today announced that one-time lifileucel monotherapy demonstrated unprecedented efficacy with deep, durable responses across two difficult-to-treat soft tissue sarcomas with limited treatment options, metastatic UPS and DDLPS, in a pilot trial presented orally at the ESMO Congress 2026 in Madrid, Spain.

Among the first eight evaluable patients, physician-assessed confirmed ORR by RECIST v1.1 was 50%. Four partial responses (2 in UPS and 2 in DDLPS) were all ongoing (at 6+, 26+, 40+, and 46+ weeks) as of the data cut-off on September 9, 2026. The eight evaluable patients had deep responses despite significant disease burden (range in baseline target sum of diameters: 39.0 to 177.6 mm), were refractory to prior lines of systemic therapy (range: 1-7), and received lifileucel that met pre-determined manufacturing specifications. The safety profile was consistent with the lifileucel treatment regimen across other indications.

Soft tissue sarcomas are rare and highly heterogeneous cancers comprising approximately 80 tumor subtypes, with an estimated incidence of 4–5 cases per 100,000 people annually in Europe and ~3.5 new diagnoses per 100,000 people in the United States each year.